Insufficient scRNA-seq data for expression of PLA2G2F at single-cell level.
Insufficient scRNA-seq data for expression of PLA2G2F at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 62% | 1486.33 | 13 / 21 | 57% | 36.43 | 287 / 504 |
ureter | 0% | 0 | 0 / 0 | 100% | 28.23 | 1 / 1 |
skin | 72% | 1362.88 | 1296 / 1809 | 6% | 0.24 | 26 / 472 |
tonsil | 0% | 0 | 0 / 0 | 40% | 1.85 | 18 / 45 |
esophagus | 0% | 1.46 | 6 / 1445 | 30% | 1.19 | 55 / 183 |
uterus | 0% | 0 | 0 / 170 | 29% | 4.51 | 135 / 459 |
pancreas | 0% | 0 | 0 / 328 | 26% | 4.76 | 46 / 178 |
stomach | 2% | 4.33 | 6 / 359 | 16% | 0.60 | 45 / 286 |
intestine | 0% | 0.41 | 2 / 966 | 13% | 0.62 | 69 / 527 |
prostate | 8% | 15.00 | 19 / 245 | 5% | 0.11 | 23 / 502 |
lung | 0% | 0 | 0 / 578 | 10% | 0.43 | 111 / 1155 |
lymph node | 0% | 0 | 0 / 0 | 3% | 3.13 | 1 / 29 |
breast | 0% | 0 | 0 / 459 | 1% | 0.02 | 10 / 1118 |
kidney | 0% | 0 | 0 / 89 | 1% | 0.37 | 7 / 901 |
ovary | 0% | 0 | 0 / 180 | 0% | 0.01 | 2 / 430 |
adipose | 0% | 2.18 | 4 / 1204 | 0% | 0 | 0 / 0 |
thymus | 0% | 0 | 0 / 653 | 0% | 0.00 | 1 / 605 |
blood vessel | 0% | 0.90 | 2 / 1335 | 0% | 0 | 0 / 0 |
muscle | 0% | 0.45 | 1 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
adrenal gland | 0% | 0 | 0 / 258 | 0% | 0 | 0 / 230 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
brain | 0% | 0 | 0 / 2642 | 0% | 0 | 0 / 705 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
heart | 0% | 0 | 0 / 861 | 0% | 0 | 0 / 0 |
liver | 0% | 0 | 0 / 226 | 0% | 0 | 0 / 406 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
GO_0006644 | Biological process | phospholipid metabolic process |
GO_0036148 | Biological process | phosphatidylglycerol acyl-chain remodeling |
GO_0036150 | Biological process | phosphatidylserine acyl-chain remodeling |
GO_0036151 | Biological process | phosphatidylcholine acyl-chain remodeling |
GO_0019369 | Biological process | arachidonic acid metabolic process |
GO_0042130 | Biological process | negative regulation of T cell proliferation |
GO_0036152 | Biological process | phosphatidylethanolamine acyl-chain remodeling |
GO_0045087 | Biological process | innate immune response |
GO_0016042 | Biological process | lipid catabolic process |
GO_0050482 | Biological process | arachidonic acid secretion |
GO_0005829 | Cellular component | cytosol |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0004623 | Molecular function | phospholipase A2 activity |
GO_0005509 | Molecular function | calcium ion binding |
GO_0047498 | Molecular function | calcium-dependent phospholipase A2 activity |
GO_0005543 | Molecular function | phospholipid binding |
Gene name | PLA2G2F |
Protein name | Group IIF secretory phospholipase A2 (GIIF sPLA2) (sPLA2-IIF) (EC 3.1.1.4) (Phosphatidylcholine 2-acylhydrolase 2F) |
Synonyms | |
Description | FUNCTION: Secretory calcium-dependent phospholipase A2 that primarily targets extracellular phospholipids. Hydrolyzes the ester bond of the fatty acyl group attached at the sn-2 position of phospholipids (phospholipase A2 activity), the catalytic efficiency decreasing in the following order: phosphatidylglycerols > phosphatidylethanolamines > phosphatidylcholines > phosphatidylserines . May play a role in lipid mediator production in inflammatory conditions, by providing arachidonic acid to downstream cyclooxygenases and lipoxygenases (By similarity). . |
Accessions | Q9BZM2 ENST00000375102.4 [Q9BZM2-2] |